BCL2 and acute myeloid leukemia: The median OS tended to be prolonged in the BCL-2− subgroup, with nearly a doubling of the OS time for IC-treated BCL-2− AML patients as compared to their BCL-2+ counterparts (22.2 months vs. 13.3 months; p = 0.0778).